Page 4702. In Figure 2, the chemical structure of compound **19** (DG-051) was incorrectly drawn as the (*R*)-enantiomer. Compound **19** is the (*S*)-enantiomer and is properly shown in the three-dimensional crystal structure image at the right-hand side in the corrected figure below.

![Panels showing ligand binding to LTA4H for compounds described in the manuscript. Enzyme assay IC~50~ values are in μM, human whole blood cell assay IC~50~ values are in nM when reported, and ligand efficiency (LE) values are in kcal/(mol·heavy atom). Compound structures are displayed as yellow stick structures, and LTA4H is displayed in gray. Green mesh corresponds to the *F*~o~ − *F*~c~ (difference) electron density at the 3.0σ level of the crystal structure with the compound omitted from the model. Polar contacts with LTA4H and/or bound water molecules are shown as red dashed lines. PDB IDs for each structure are indicated.](jm-2010-00015w_0001){#fig2}

On page 4704, right hand column, first paragraph, line 19 and second paragraph line 22, (*R*)-prolinol should be changed to (*S*)-prolinol.

Supporting Information Page S16. In Table 2, the chemical structure of compound **19** (DG-051) was incorrectly drawn as the (*R*)-enantiomer. The correct (*S*)-enantiomer has been included in the revised version of Supplemental Table 2 below.

###### Supplemental Table 2. Comparative IC~50~ data for peptidase, hydrolase, and HWB assays.

  --
  --

**Supplemental Table 2. Comparative IC**~**50**~**data for peptidase, hydrolase, and HWB assays.** For all compound structures described in this work, inhibition assays were carried out using at least two independent methods, either the hydrolase assay, peptidase assay and/or a hydrolase assay in human whole blood. See Materials and Methods section for details. All results are given as IC~50~ values in μM, with the number of replicates and the standard error of the mean indicated where applicable.
